SpringerLink
Log in

The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Treatment with dopamine agonists in patients with prolactinomas has been associated with weight loss in short term studies. However, long-term studies on weight changes are lacking. Taq1A is a restriction fragment length polymorphism considered as a gene marker for the DRD2 gene. The presence of at least one A1 allele is linked to reduced brain dopaminergic activity due to reduced receptor binding and lower density of the dopamine 2 receptor. We aimed at testing the hypothesis that the dopaminergic treatment in prolactinoma patients leads to sustained weight loss and that the presence of diminished weight loss response under dopamine agonists is associated with the minor A1 allele of Taq1A.We included n = 44 patients (17 male and 27 female, 26 macroadenomas and 18 microadenomas) with prolactinomas treated with dopamine agonists. Outcome measures were weight and body mass index (BMI) change under dopaminergic treatment after 2 years with regard to Taq1A status and sex. We observed that the dopaminergic treatment leads to a significant mean weight loss of 3.1 ± 6.25 kg after 2 years. Regarding Taq1A polymorphisms, 21 patients were carriers of at least one A1 allele and 23 patients had a genotype of A2/A2. However, the presence of the A1 allele was neither associated with the mean BMI at baseline nor with an altered weight loss response under dopamine agonist therapy. Our results implicate that the dopaminergic treatment leads to a sustained weight loss in patients with prolactinomas after 2 years. However, there was no association to the A1 allele of Taq1A, observation that needs to be analysed in larger cohorts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64(4):366–370. doi:10.1111/j.1365-2265.2006.02469.x

    CAS  Google Scholar 

  2. Schmid C, Goede DL, Hauser RS, Brandle M (2006) Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 136(15–16):254–258. doi:http://www.smw.ch/docs/pdf200x/2006/15/smw-10955.PDF

    PubMed  Google Scholar 

  3. Greenman Y, Tordjman K, Stern N (1998) Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 48(5):547–553

    Article  CAS  Google Scholar 

  4. Korner J, Lo J, Freda PU, Wardlaw SL (2003) Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res 11(2):311–312

    Article  CAS  PubMed  Google Scholar 

  5. Berinder K, Nystrom T, Höybye C, Hall K, Hulting A-L (2011) Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14(3) 199–207. doi:10.1007/s11102-010-0277-9

    Google Scholar 

  6. Silva CMD, Barbosa FRP, Lima GAB, Warszawski L, Fontes R, Domingues RC, Gadelha MR (2011) BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19(4):800–805. doi:10.1038/Oby.2010.150

    Article  Google Scholar 

  7. Munafo MR, Matheson IJ, Flint J (2007) Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Mol Psychiatry 12(5):454–461. doi:10.1038/sj.mp.4001938

    CAS  PubMed  Google Scholar 

  8. Smith L, Watson M, Gates S, Ball D, Foxcroft D (2008) Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review. Am J Epidemiol 167(2):125–138. doi:10.1093/aje/kwm281

    Article  PubMed  Google Scholar 

  9. Stice E, Spoor S, Bohon C, Small DM (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322(5900):449–452. doi:10.1126/science.1161550

    Article  CAS  PubMed  Google Scholar 

  10. Ritchie T, Noble EP (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28(1):73–82

    Article  CAS  PubMed  Google Scholar 

  11. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 3(3):256–260

    Article  CAS  PubMed  Google Scholar 

  12. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2) 273–288. doi:10.1210/jc.2010-1692

    Google Scholar 

  13. Cole TJ, Bellizzi M, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320(7244):1240–1243

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Athanasoulia AP, Sievers C, Ising M, Brockhaus AC, Yassouridis A, Stalla GK, Uhr M (2012) Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 167(3) 327–335 doi:10.1530/EJE-12-0198

    Google Scholar 

  15. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E (2007) Hypopituitarism. Lancet 369(9571):1461–1470. doi:10.1016/S0140-6736(07)60673-4

    Article  CAS  PubMed  Google Scholar 

  16. Cincotta AH, Meier AH (1996) Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 19(6):667–670

    Article  CAS  PubMed  Google Scholar 

  17. Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J (2012) Randomized pilot study of cabergoline a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes Metab 14(4) 335–340. doi:10.1111/j.1463-1326.2011.01534.x

  18. Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C (2013) Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). doi:10.1111/cen.12204

  19. Via MA, Chandra H, Araki T, Potenza MV, Skamagas M (2010) Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 3:43–48

    Google Scholar 

  20. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147(1):77–84

    Article  CAS  PubMed  Google Scholar 

  21. Yermus R, Ezzat S (2002) Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol (Oxf) 56(4):562

    Article  CAS  Google Scholar 

  22. Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinol 96(3):204–211

    Google Scholar 

  23. Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A (2007) Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf) 67(6):845–852. doi:10.1111/j.1365-2265.2007.02973.x

    Article  CAS  Google Scholar 

  24. Borcherding DC, Hugo ER, Idelman G, De Silva A, Richtand NW, Loftus J, Ben-Jonathan N (2011) Dopamine receptors in human adipocytes: expression and functions. PLoS One 6(9):e25537. doi:10.1371/journal.pone.0025537

  25. Mukherjee R, Yun JW (2013) Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on alpha2-adrenergic receptor in 3T3-L1 adipocyte cells. Mol Biol Rep 40(5) 3783–3792. doi:10.1007/s11033-012-2455-5

  26. Ariza M, Garolera M, Jurado MA, Garcia–Garcia I, Hernan I, Sanchez-Garre C, Vernet–Vernet M, Sender-Palacios MJ, Marques-Iturria I, Pueyo R, Segura B, Narberhaus A (2012) Dopamine genes (DRD2/ANKK1-TaqA1 and DRD4-7R) and executive function: their interaction with obesity. PLoS One 7(7):e41482. doi:10.1371/journal.pone.0041482

  27. Huang W, Payne TJ, Ma JZ, Beuten J, Dupont RT, Inohara N, Li MD (2009) Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacol 34(2):319–330. doi:10.1038/npp.2008.37

    Article  CAS  Google Scholar 

  28. Cameron JD, Riou ME, Tesson F, Goldfield GS, Rabasa-Lhoret R, Brochu M, Doucet E (2013) The TaqIA RFLP is associated with attenuated intervention-induced body weight loss and increased carbohydrate intake in post-menopausal obese women. Appetite 60(1):111–116. doi:10.1016/j.appet.2012.09.010

    Google Scholar 

  29. Winkler JK, Woehning A, Schultz JH, Brune M, Beaton N, Challa TD, Minkova S, Roeder E, Nawroth PP, Friederich HC, Wolfrum C, Rudofsky G (2012) TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients. Nutrition 28(10):996–1001. doi:10.1016/j.nut.2011.12.018

    Google Scholar 

Download references

Conflict of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Endocrinology and Clinical Chemistry, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804, Munich, Germany

    A. P. Athanasoulia, C. Sievers & G. K. Stalla

  2. Department of Pharmacokinetics and CSF Analysis, Kraepelinstrasse 2-10, 80804, Munich, Germany

    M. Uhr

  3. Department of Molecular Psychology, Kraepelinstrasse 2-10, 80804, Munich, Germany

    M. Ising

  4. Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, Ziemssenstr. 1, 80336, Munich, Germany

    H. J. Schneider

Authors
  1. A. P. Athanasoulia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Sievers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Uhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Ising
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. K. Stalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. J. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. P. Athanasoulia.

Additional information

A. P. Athanasoulia and C. Sievers shared first authorship.

G. K. Stalla and H. J. Schneider shared last authorship.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Athanasoulia, A.P., Sievers, C., Uhr, M. et al. The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. Pituitary 17, 240–245 (2014). https://doi.org/10.1007/s11102-013-0496-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-013-0496-y

Keywords

Search

Navigation